Medpace Holdings Inc vs OneSpan Inc — how do they compare? Medpace Holdings Inc trades at $530.58 (market cap $15.08B), while OneSpan Inc trades at $15.31 (market cap $575.37M). The key difference: Medpace Holdings Inc is far larger — about 26.2× OneSpan Inc's market cap, and OneSpan Inc pays a 3.35% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | OSPN | |
|---|---|---|
Market Cap | $15.08B | $575.37M |
Sector | Technology | Technology |
52-Week High | $620.59 | $16.32 |
52-Week Low | $308.88 | $10.15 |
Enterprise Value | $14.55B | $533.57M |
Dividend Yield | — | 3.35% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
OneSpan (OSPN) trades at $15.51, showing modest daily gains of 0.26% with strong technical momentum indicated by bullish moving averages. The company demonstrates robust profitability with a 28.47% net income margin and consistent earnings beats in recent quarters. Recent corporate developments include a $0.13 dividend payment and upcoming Q2 2026 earnings announcement on August 4, 2026.
The stock presents attractive valuation metrics with a P/E of 8.55 and strong analyst support (66.7% buy ratings), though current price exceeds the $13.50 consensus target. Key risks include negative cash flow trends and competitive pressures in the cybersecurity sector. Earnings growth remains the primary catalyst for further upside potential.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →